|1||Active, not recruiting||
A Safety Study of SGN-CD33A in AML Patients
|2||Active, not recruiting||
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
† Study has passed its completion date and status has not been verified in more than two years.